Fig 5

Systemic administration of liposome-encapsulated rosiglitazone (LER) confers neuroprotection to neurons in the retina and in the nigrostriatal pathway. a Schematic overview of the treatment regimens. b Upon administration of liposome-encapsulated rosiglitazone, every 3 days during the 60-days rotenone treatment (LER60), a neuroprotective effect on tyrosine hydroxylase-positive dopaminergic neurons is seen in the SN. This is not the case when daily injections of unencapsulated rosiglitazone are given (RCG60). c A preservative trend of tyrosine hydroxylase-positive efferent fibers in the striatum, in comparison to rotenone only (Rot60), vehicle (empty liposomes) and unencapsulated rosiglitazone (RCG60) rats, is also seen in the striatum